My Companies
Notification
Account
Log Out
Login
Anupam Rasayan completed acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299/share, funded by a ₹300 crore term loan and ~₹1,450 crore of non-controlling, non-voting instruments. The combined platform is expected to exceed ₹4,000 crore revenue with ~₹834 crore EBITDA. Context: Bliss acquisition overhang resolved.
Anupam Rasayan Creates Additional 2.16 Percent Pledge Raising Encumbrance To 17.07 Percent
Anupam Rasayan Promoter Mona Desai Encumbers 97.58 Percent Shareholding For NCDs
Anupam Rasayan India Pledges Additional 66 Lakh Shares Taking Encumbrance To 14.9%
Anupam Rasayan Promoters Pledge 1.20 Crore Shares For Debt Security
Anupam Rasayan Promoters Pledge 9.10% Equity Shares To Catalyst Trustee